ID   WAC2
AC   CVCL_0575
SY   WAC-2; WAC 2
DR   MCCL; MCC:0000481
DR   cancercelllines; CVCL_0575
DR   Wikidata; Q54993536
RX   PubMed=2364393;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; HGNC:427; ALK; Simple; p.Phe1174Leu (c.3522C>A); ClinVar=VCV000217852; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Bone marrow; UBERON=UBERON_0002371.
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0522 ! SH-EP007
SX   Female
AG   4Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 17
//
RX   PubMed=2364393;
RA   Schweigerer L., Breit S., Wenzel A., Tsunamoto K., Ludwig R.,
RA   Schwab M.;
RT   "Augmented MYCN expression advances the malignant phenotype of human
RT   neuroblastoma cells: evidence for induction of autocrine growth factor
RT   activity.";
RL   Cancer Res. 50:4411-4416(1990).
//